about
Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers.Mouse models for filovirus infectionsMolecular determinants of Ebola virus virulence in mice.Development and characterization of a mouse model for Marburg hemorrhagic feverA DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trialMonovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses.Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trialAdvances in virus-like particle vaccines for filoviruses.The evolving field of biodefence: therapeutic developments and diagnostics.Filovirus-like particles as vaccines and discovery tools.Development of a model for marburgvirus based on severe-combined immunodeficiency mice.Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1.Evaluation of Different Strategies for Post-Exposure Treatment of Ebola Virus Infection in Rodents.Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family FiloviridaeProtection against filovirus infection: virus-like particle vaccines.Protection against lethal challenge by Ebola virus-like particles produced in insect cells.Replication-deficient ebolavirus as a vaccine candidate.Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infectionImmune parameters correlate with protection against ebola virus infection in rodents and nonhuman primatesFibroblastic reticular cells and their role in viral hemorrhagic fevers.Protective role of cytotoxic T lymphocytes in filovirus hemorrhagic fever.Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.Future Approaches to DNA Vaccination Against Hemorrhagic Fever Viruses.Intradermal immunization by Ebola virus GP subunit vaccines using microneedle patches protects mice against lethal EBOV challenge
P2860
Q25256700-9B629F23-77F6-4491-92F9-0561270C06C1Q27011569-EC7D578C-B9B9-46E4-B6F9-83B3EC688866Q33250567-73774073-4A6F-4AE7-917A-65E9AD945B77Q33384111-6D3B96F1-8F66-4A87-8EF1-B7F332147DBBQ34571072-58A115E4-E418-4DFF-A597-072D2E4FC423Q34774783-7CF08A58-C3C6-481F-B704-6B4298C67AD5Q35055198-9AE74BFE-D3D1-42CE-B11C-388F000ECC5BQ35300029-9D5AD40D-B923-40B0-8825-4CA83E2A82FBQ36085668-9F7A255C-EE86-440A-8F1B-C426B43AB19CQ36198685-20707C6B-3BE2-45EB-8086-2A6635D41897Q36310674-B33684B1-3725-458A-B707-2B66380A5F60Q36315139-FFD597F7-A9A3-4D2F-BFE2-182988D38D6EQ36433538-DF8C1630-F227-4F40-8FEC-A55C0C1BA588Q36893352-9C51D4BE-4414-4079-9711-29D464C5E562Q37130463-B2A057C3-4CC1-43C4-B340-EF87C53205EDQ37131622-A27FE5C3-CEE1-4455-9EA2-FF040E92D8F8Q37145203-6A6F9709-EB59-40F0-9E4F-B113F0CA537DQ37190830-A6F7842F-4E85-4885-A4F2-D9C56885F051Q37213207-7B0262E8-2C60-4D94-8EC0-04C7E9358AE3Q37463214-17EF7FA9-2727-4D38-BCEE-099AE7F5D6E6Q37976671-374BBD02-EBFB-4B3F-A088-8517750EF3EDQ40311630-E04D4D6B-C1A4-40E3-BC6B-4F9BACBDAB7CQ41922339-8F07D7D0-8877-4828-ACD6-D0D2F3AACEEDQ56945995-A48C28B1-9C74-43CC-9F64-E4C1735880B5
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Vaccine research efforts for filoviruses.
@ast
Vaccine research efforts for filoviruses.
@en
type
label
Vaccine research efforts for filoviruses.
@ast
Vaccine research efforts for filoviruses.
@en
prefLabel
Vaccine research efforts for filoviruses.
@ast
Vaccine research efforts for filoviruses.
@en
P1476
Vaccine research efforts for filoviruses.
@en
P2093
Mary Kate Hart
P304
P356
10.1016/S0020-7519(03)00064-X
P577
2003-05-01T00:00:00Z